References
Wirdefeldt K, Odin P, Nyholm D. Levodopa-carbidopa intestinal gel in patients with Parkinson’s disease: a systematic review. CNS Drugs. 2016;30(5):381–404.
Olanow CW, Kieburtz K, Odin P, Espay AJ, Standaert DG, Fernandez HH, et al. Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson’s disease: a randomised, controlled, double-blind, double-dummy study. Lancet Neurol. 2014;13(2):141–9.
Slevin JT, Fernandez HH, Zadikoff C, Hall C, Eaton S, Dubow J, et al. Long-term safety and maintenance of efficacy of levodopa-carbidopa intestinal gel: an open-label extension of the double-blind pivotal study in advanced Parkinson’s disease patients. J Parkinsons Dis. 2015;5(1):165–74.
Aarsland D, Andersen K, Larsen JP, Lolk A. Prevalence and characteristics of dementia in parkinson disease: an 8-year prospective study. Arch Neurol. 2003;60(3):387–92.
DANMODIS, Danish Movement Disorder Society; SWEMODIS SMDS. Treatment with levodopa/carbidopa gel (Duodopa) in patients with Parkinson’s disease [Internet]. 2008. http://parkinsoninfo.parkinsonforbundet.se/wp-content/uploads/duodopakonsensus-20081.pdf. Accessed 28 July 2016.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
No funding was received for this publication.
Conflicts of interest
Andrew Lambarth has no conflicts of interest associated with this article.
Rights and permissions
About this article
Cite this article
Lambarth, A.T. Comment on: “Levodopa-Carbidopa Intestinal Gel in Patients with Parkinson’s Disease: A Systematic Review”. CNS Drugs 30, 1007–1008 (2016). https://doi.org/10.1007/s40263-016-0378-8
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40263-016-0378-8